BioNTech (NASDAQ:BNTX) Shares Down 3.3% – Should You Sell?

BioNTech SE (NASDAQ:BNTX)’s stock price fell 3.3% during trading on Friday . The company traded as low as $108.75 and last traded at $110.66. 741,146 shares were traded during mid-day trading, a decline of 6% from the average session volume of 786,373 shares. The stock had previously closed at $114.47.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BNTX. HC Wainwright increased their price objective on shares of BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and increased their target price for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. Bank of America increased their target price on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. Finally, TD Cowen reduced their price objective on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research note on Tuesday, August 6th. Five analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.92.

BioNTech Stock Down 2.8 %

The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $26.46 billion, a P/E ratio of 224.98 and a beta of 0.24. The stock’s 50 day simple moving average is $103.95 and its 200 day simple moving average is $94.05.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same quarter in the previous year, the business posted ($0.86) earnings per share. The company’s quarterly revenue was down 23.3% compared to the same quarter last year. As a group, research analysts predict that BioNTech SE will post -3.04 EPS for the current fiscal year.

Institutional Trading of BioNTech

Several large investors have recently added to or reduced their stakes in BNTX. GAMMA Investing LLC lifted its holdings in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the last quarter. Covestor Ltd boosted its holdings in shares of BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after buying an additional 133 shares during the period. EverSource Wealth Advisors LLC grew its stake in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after buying an additional 252 shares during the last quarter. Blue Trust Inc. raised its holdings in BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares during the period. Finally, Crewe Advisors LLC bought a new stake in BioNTech during the first quarter valued at about $75,000. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.